BCCM has become observer member of GGBN


The BCCM consortium has joined the Global Genome Biodiversity Network (GGBN) as observer member. The GGBN is a global network of well-managed collections of genomic tissue samples from across the Tree of Life, benefiting society through biodiversity research, development and conservation. The BCCM collections  offer their microbial strains also as genomic DNA samples, and want to share their experiences with  other colleagues in the genomics field.

PERN: an EU–Russia initiative for rhizosphere microbial resources


Millions of microbial taxa inhabit the rhizosphere and could be used as biofertilizers, biopesticides, and/or for bioremediation. Only a fraction of these microbes have been described and/or are being utilized. Most are dispersed in collections, but coordination of their accessibility and availability is challenging. Here, we present the Pan-European Rhizosphere Resource Network (PERN), which is a transnational repository of microorganisms whose objectives are to facilitate access to rhizosphere resources and information and help users with technical and legal issues.

BCCM/IHEM is certified ISO 14001 for its environmental policy


Since January 2015, the Scientific Institute of Public Health (WIV-ISP) hosting the BCCM/IHEM collection has been certified ISO 14001 for its environmental policy. This certification involves that the institute is committed to a sustainable management of its activities. The latter include waste reduction, energy saving, the compliance with and follow-up of the regulation, the analysis, surveillance and reduction of its environmental impact.

MIRRI - updates on the progress of the establishment of the Microbial Resource Research Infrastructure


MIRRI is a pan-European distributed research infrastructure in its Preparatory Phase which aims to support research and development in the field of biotechnology. Issue 3 of  MIRRI newsletter provides updates on the progress of the establishment of the Microbial Resource Research Infrastructure.



Novel bicistronic cloning vector set based on P2A peptide


When expressing more than one gene in a cell line, often bicistronic expression vectors with an internal ribosomal entry site (IRES) are used. Instead of these large IRES sequences, a much shorter, self-cleaving 2A peptide (P2A) can be used. The efficient cleaving activity of this peptide was described in Kim et al. (2011; PMID: 21602908).

To make the advantages of the P2A peptide available for all scientists, BCCM/LMBP is proud to announce the bicistronic pEF6-P2A cloning vector.

Workshop on MALDI-TOF MS for the identification of Fungi


The 19th congress of the International Society of Human and Animal Mycology (ISHAM) will take place from the 4th until the 8th of May in Melbourne, Australia. BCCM/IHEM is involved in the organization of a workshop on MALDI-TOF MS for the identification of fungi, on the 3th of May. More information can be found here:

We are hoping to welcome you in Melbourne!

Human ORFeome v8.1 - find your gene in a Gateway Entry vector at LMBP


The hORFv8.1 library consists of a sequence-verified, clonal collection of human Open Reading Frames (ORFs), presented as individual Gateway Entry vectors (backbone: pDONR223). 

The new BCCM/LMBP search engine makes the quest for your gene of interest easy, with a database containing, among others, all names and symbols ever assigned to it.

All clones come without a termination codon, allowing the addition of C-terminal tags or markers.

Bedaquiline- and clofazimine-resistant Mycobacterium tuberuclosis reference strains available in public collection of mycobacterial strains BCCM/ITM


The global burden of multi-drug tuberculosis (MDR-TB) was estimated  in 2013 at  5.3% of TB cases, including  9% with extensively drug-resistant tuberculosis (XDR-TB)1.  Only 48% of MDR cases were treated successfully, in part due to high toxicity, the long duration of the current regimens, and drug supply interruptions. To overcome these constraints, new TB drugs were deemed essential  and have been  developed, yet their safety and efficacy are being assessed in Phase II and III clinical trials for patients with MDR-TB.